Amphera is pleased to announce that the results of the REACTIVE-2 trial in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) following standard of care chemotherapy have been published in Nature Communications. The REACtiVe-2 trial evaluated the safety, tolerability and immunological effects of MesoPher cell therapy in combination with CD40 agonist mitazalimab, developed by Alligator Bioscience.
MesoPher/mitazalimab combination therapy is proven safe and tolerable in patients with metastatic PDAC. Furthermore, this therapy enhances systemic immune activation and induces favourable tumour-microenvironment changes with increased intratumoral T-cell presence.
The study produced a wealth of translational data that further solidify the scientific foundation of MesoPher cell therapy and illustrate the excellent and safe combination potential of MesoPher cell therapy with other immune therapies in hard to treat cancers.